XML 46 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Note 4 - Income Taxes - Component of Deferred Tax Assets (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Stock option expense $ 1,341,900 $ 947,400
NOL carryforward 11,524,900 10,509,900
Research and development credits 1,623,100 1,656,500
Section 174 - R&D expenses 1,046,400 0
Unrealized gain from investment in Alphazyme 0 (72,100)
Other (78,200) (6,100)
Deferred tax asset, net of deferred tax liabilities 15,458,100 13,035,600
Valuation allowance (15,458,100) (13,035,600)
Net deferred tax asset $ 0 $ 0